Development

HDM2006: First-in-Human Phase 1 Trial Explores HPK1 Inhibition in Advanced Solid Tumors

Researchers at Fudan University Shanghai Cancer Center have initiated a first-in-human clinical trial investigating HDM2006, an experimental drug targeting the Hematopoietic Progenitor Kinase 1 (HPK1) pathway in patients with advanced solid tumors. The [Phase 1 study](https://clinicaltrials.gov/study/NCT07377591) represents a critical early step in evaluating the safety, tolerability, and potentia

Edited by Robert McTiernan··3 min read

Novel HPK1 Inhibitor HDM2006 Enters First-in-Human Trial for Advanced Solid Tumors

Researchers at Fudan University Shanghai Cancer Center have initiated a first-in-human clinical trial investigating HDM2006, an experimental drug targeting the Hematopoietic Progenitor Kinase 1 (HPK1) pathway in patients with advanced solid tumors. The Phase 1 study represents a critical early step in evaluating the safety, tolerability, and potential efficacy of this novel investigational therapy.

Trial Design and Objectives

The clinical trial employs a sophisticated adaptive design, featuring both dose escalation and expansion phases. Researchers will enroll 48 adult patients with advanced solid tumors, systematically exploring different dose levels of HDM2006 to determine its safety profile and optimal dosing strategy. The trial will utilize oral administration, with patients receiving the drug within 30 minutes after a meal.

Primary endpoints include comprehensive safety assessments, including the incidence and severity of adverse events, as well as identifying a recommended Phase 2 dose. Notably, the study will also examine pharmacodynamic markers, including changes in HPK1 and pSLP-76 expression in tumor tissues—providing crucial insights into the drug's potential molecular mechanisms.

Research Context and Molecular Rationale

HPK1 inhibition represents an emerging strategy in cancer therapeutics, targeting cellular signaling pathways that potentially modulate immune response and tumor progression. While the precise molecular details of HDM2006 remain proprietary, the trial's design suggests a sophisticated approach to interrupting cancer cell signaling mechanisms.

Competitive Landscape of HPK1 Inhibition

The first-in-human trial enters a nascent but competitive developmental landscape. Several companies are exploring HPK1 inhibition, including:

  • Treadwell Therapeutics: CFI-402411 (Phase 1/2)
  • BeiGene: BGB-15025 and BGB-26808 (Phase 1)
  • Glenmark Specialty: GRC 54276 (Phase 1)
  • BrodenBio: BB3008 (Phase 1)

Geographically, the research is predominantly concentrated in China, with additional activity in India, the United States, and Australia—reflecting a global interest in this therapeutic approach.

The AllSci BriefSystematic R&D and deal news. Daily.

Clinical Development Strategy

The trial's adaptive design demonstrates a methodical approach to first-in-human clinical research. By incorporating both dose escalation and expansion phases, researchers can:

  • Establish a safe dosing range
  • Identify potential efficacy signals
  • Collect critical pharmacodynamic data
  • Prepare for potential subsequent development phases

Enrollment is currently underway at Fudan University Shanghai Cancer Center, with patients being carefully selected based on stringent inclusion criteria, including:

  • Advanced solid tumor diagnosis
  • ECOG Performance Status of 0-1
  • Adequate organ function
  • No concurrent participation in other interventional studies

Broader Implications for Cancer Research

While it's premature to draw definitive conclusions, this first-in-human trial represents an important exploratory effort in understanding HPK1's role in cancer progression. The study's comprehensive approach—examining not just safety, but molecular changes—reflects the evolving paradigm of precision oncology.

The trial will track multiple secondary endpoints, including:

  • Time to Response
  • Duration of Response
  • Objective Response Rate
  • Progression-free Survival
  • Overall Survival

As the first-in-human trial progresses, researchers and clinicians will be watching closely to understand HDM2006's potential in addressing unmet needs in advanced solid tumor treatment.

Spot something wrong? Report an issue with this article